| Nome |
# |
|
In-vitro evaluation of a new benzomorphan-based ligand, file dfe4d228-83d3-bb0a-e053-d805fe0a78d9
|
467
|
|
Simultaneous activation of mu and delta opioid receptors reduces allodynia and astrocytic connexin 43 in an animal model of neuropathic pain, file dfe4d229-e51c-bb0a-e053-d805fe0a78d9
|
193
|
|
In Vitro Antioxidant Activity and In Vivo Topical Efficacy of Lipid Nanoparticles Co-Loading Idebenone and Tocopheryl Acetate, file dfe4d229-8e7f-bb0a-e053-d805fe0a78d9
|
132
|
|
Rosemary Essential Oil-Loaded Lipid Nanoparticles: In Vivo Topical Activity from Gel Vehicles, file dfe4d228-6ea1-bb0a-e053-d805fe0a78d9
|
108
|
|
Synthesis and structure-activity relationships of (–)-cis-N-normetazocine-based LP1 derivatives, file dfe4d229-0274-bb0a-e053-d805fe0a78d9
|
36
|
|
Mu and Delta Opioid Receptor Targeting Reduces Connexin 43-Based Heterocellular Coupling during Neuropathic Pain, file 787a4eae-ae28-42e4-9c5b-e6ffe33803c3
|
25
|
|
Synthesis and Structure-Activity Relationships of LP1 Derivatives: N-Methyl-N-phenylethylamino Analogues as Novel MOR Agonists, file dfe4d228-dc11-bb0a-e053-d805fe0a78d9
|
18
|
|
Resveratrol-loaded lipid nanocarriers: Correlation between in vitro occlusion factor and in vivo skin hydrating effect, file dfe4d228-9524-bb0a-e053-d805fe0a78d9
|
15
|
|
Discovery of AD258 as a Sigma Receptor Ligand with Potent Antiallodynic Activity, file fe5420ee-d461-4cae-a84e-7bc26d42506f
|
11
|
|
New Insights into the Opioid Analgesic Profile of cis-(-)-N-Normetazocine-derived Ligands, file 6db428fa-2b5c-4ccb-a8b9-c2dd16f669ab
|
9
|
|
Idebenone: Novel strategies to improve its systemic and local efficacy, file dfe4d228-ac57-bb0a-e053-d805fe0a78d9
|
9
|
|
In Vitro Evaluation of Sunscreen Safety: Effects of the Vehicle and Repeated Applications on Skin Permeation from Topical Formulations, file dfe4d228-c1c6-bb0a-e053-d805fe0a78d9
|
9
|
|
Haloperidol Metabolite II Valproate Ester (S)-(-)-MRJF22: Preliminary Studies as a Potential Multifunctional Agent Against Uveal Melanoma, file dfe4d22e-52b1-bb0a-e053-d805fe0a78d9
|
9
|
|
The Multimodal MOPr/DOPr Agonist LP2 Reduces Allodynia in Chronic Constriction Injured Rats by Rescue of TGF-β1 Signalling, file dfe4d22e-5536-bb0a-e053-d805fe0a78d9
|
8
|
|
Design, synthesis, in vitro evaluation, and molecular modeling studies of N-substituted benzomorphans, analogs of LP2, as novel MOR ligands, file c2cdfff2-b964-4334-90bc-644a48d95784
|
7
|
|
Nonpeptide Analogues of Dynorphin A(1-8): Design, Synthesis, and Pharmacological Evaluation of k-Selective Agonists, file dfe4d227-48b7-bb0a-e053-d805fe0a78d9
|
6
|
|
Influenza del N-sostituente della (–)-cis-N-Normetazocina nella modulazione del profilo funzionale al MOR, DOR e KOR: da agonista ad antagonista attraverso ligandi misti agonisti/antagonisti, file dfe4d229-8dd4-bb0a-e053-d805fe0a78d9
|
6
|
|
Neuroprotective effects of Rosmarinus officinalis L. extract in oxygen glucose deprivation (OGD)-injured human neural-like cells, file dfe4d229-a533-bb0a-e053-d805fe0a78d9
|
6
|
|
Lp1 and lp2: Dual‐target mopr/dopr ligands as drug candidates for persistent pain relief, file dfe4d22e-598b-bb0a-e053-d805fe0a78d9
|
6
|
|
Novel N-normetazocine Derivatives with Opioid Agonist/Sigma-1 Receptor Antagonist Profile as Potential Analgesics in Inflammatory Pain, file 27e3a036-d724-4d51-9242-ad75ac53e98b
|
5
|
|
CCB, a novel specific kappa opioid agonist, which discriminates between opioid
and sigma 1 recognition sites, file dfe4d227-0b3c-bb0a-e053-d805fe0a78d9
|
5
|
|
Exploiting the Power of Stereochemistry in Drug Action: 3-[(2S,6S,11S)-8-Hydroxy-6,11-dimethyl-1,4,5,6-tetrahydro-2,6-methano-3-benzazocin-3(2H)-yl]-N-phenylpropanamide as Potent Sigma-1 Receptor Antagonist, file dfe4d22a-eed3-bb0a-e053-d805fe0a78d9
|
5
|
|
Solid lipid nanoparticles as carriers for the synthetic opioid lp2: Characterization and in vitro release, file dfe4d22e-ba3d-bb0a-e053-d805fe0a78d9
|
5
|
|
Caspase-3 activation in human melanoma A375 cell line by a novel selective sigma-2 agonist, file dfe4d227-171c-bb0a-e053-d805fe0a78d9
|
4
|
|
Differential scanning calorimetry approach to investigate the transfer of the multitarget opioid analgesic LP1 to biomembrane model, file dfe4d227-27ba-bb0a-e053-d805fe0a78d9
|
4
|
|
The multitarget opioid ligand LP1's effects in persistent pain and in primary cell neuronal cultures, file dfe4d227-b385-bb0a-e053-d805fe0a78d9
|
4
|
|
The multitarget opioid ligand LP1's effects in persistent pain and in primary cell neuronal cultures, file dfe4d227-b386-bb0a-e053-d805fe0a78d9
|
4
|
|
Synthesis and in vitro opioid receptor studies on benzomorphan-based compounds: LP1, a potent and long-acting antinociceptive, file dfe4d228-8448-bb0a-e053-d805fe0a78d9
|
4
|
|
R- ed S-LP2: sintesi, molecular docking e valutazione farmacologica, file dfe4d228-b3d2-bb0a-e053-d805fe0a78d9
|
4
|
|
MOR/DOR targeting: an useful strategy in pain management, file dfe4d229-8a9d-bb0a-e053-d805fe0a78d9
|
4
|
|
LP2 e 2S-LP2: agonisti biased dual target MOR/DOR nel trattamento del dolore cronico, file dfe4d229-8efb-bb0a-e053-d805fe0a78d9
|
4
|
|
MOR/DOR targeting: an useful strategy in pain management, file dfe4d229-9745-bb0a-e053-d805fe0a78d9
|
4
|
|
Discovery of first novel sigma/HDACi dual-ligands with a potent in vitro antiproliferative activity, file f9f8dca3-6ec7-4221-9c41-4760b5c358e4
|
4
|
|
Antiproliferative activity of phenylbutyrate ester of haloperidol metabolite II [(±)-MRJF4] in prostate cancer cells, file dfe4d226-f429-bb0a-e053-d805fe0a78d9
|
3
|
|
The antagonistic effect of the sigma 1 receptor ligand (+)-MR200 on persistent pain induced by inflammation., file dfe4d227-2540-bb0a-e053-d805fe0a78d9
|
3
|
|
Evaluation of N-substituent structural variations in opioid receptor profile of LP1., file dfe4d227-9330-bb0a-e053-d805fe0a78d9
|
3
|
|
Specific kappa opioid receptor agonists, file dfe4d227-ada5-bb0a-e053-d805fe0a78d9
|
3
|
|
The antagonistic effect of the sigma 1 receptor ligand (+)-MR200 on persistent pain induced by inflammation., file dfe4d227-b6ec-bb0a-e053-d805fe0a78d9
|
3
|
|
Development of novel LP1-based analogues with enhanced delta opioid receptor profile, file dfe4d228-ae77-bb0a-e053-d805fe0a78d9
|
3
|
|
Progress in the development of more effective and safer analgesics for pain management, file dfe4d22a-f2ae-bb0a-e053-d805fe0a78d9
|
3
|
|
Simultaneous targeting of MOR/DOR: A useful strategy for inflammatory pain modulation, file dfe4d22b-3e00-bb0a-e053-d805fe0a78d9
|
3
|
|
((2S)-N-2-methoxy-2-phenylethyl-6,7-benzomorphan compound (2S-LP2): Discovery of a biased mu/delta opioid receptor agonist, file dfe4d22b-3e09-bb0a-e053-d805fe0a78d9
|
3
|
|
The multitarget opioid ligand LP1's effects in persistent pain and in primary cell neuronal cultures, file dfe4d227-01d3-bb0a-e053-d805fe0a78d9
|
2
|
|
New benzomorphan derivatives of MPCB as MOP and KOP receptor ligands, file dfe4d227-7d8a-bb0a-e053-d805fe0a78d9
|
2
|
|
Caspase-3 activation in human melanoma A375 cell line by a novel selective sigma-2 agonist, file dfe4d227-ad22-bb0a-e053-d805fe0a78d9
|
2
|
|
From plant to bench: natural products as source for analgesic drug development., file dfe4d22b-4d59-bb0a-e053-d805fe0a78d9
|
2
|
|
Multitarget Opioid/Non-opioid Ligands: A Potential Approach in Pain Management, file dfe4d22b-8e63-bb0a-e053-d805fe0a78d9
|
2
|
|
A New LP1 analogue is used to better understand MOR ligand Binding Domain and its mechanisms of activation, file dfe4d22b-ff9a-bb0a-e053-d805fe0a78d9
|
2
|
|
Design, Synthesis and biological evaluation of hybrid MOR agonist/ HDACi molecules as potential therapeutic agents for chronic pain treatment, file 131a87c9-ac21-477e-a7cf-a2e8fc0282fa
|
1
|
|
Hybrid MOR agonist/HDACi molecules as potential antinociceptive multi-target drugs: design, synthesis, and biological evaluation, file 1a7a5ca9-a377-47d5-aba0-901964b5cd87
|
1
|
|
Design, synthesis and biological evaluation of MOR agonist/HDACi hybrid compounds: a new potential therapeutic strategy for persistent pain management, file 1bcecb82-bba6-40db-82aa-2e0a29029734
|
1
|
|
Hybrid MOR agonist/HDACi molecules as potential new drugs for persistant pain management: design, synthesis and biological evaluation, file 278ca3de-af66-4370-9bff-d32e4e4963fb
|
1
|
|
Simultaneous targeting of MOR/DOR: A useful strategy for inflammatory pain modulation, file 3bf57ea2-9319-4da4-a703-6fd1777fef0b
|
1
|
|
Synthesis, Computational Insights, and Evaluation of Novel Sigma Receptors Ligands, file 61713f9d-aa40-4ca6-9f1a-63a80ea247ea
|
1
|
|
Novel N-Substituted Benzomorphan-Based Compounds: From MOR-Agonist/DOR-Antagonist to Biased/Unbiased MOR Agonists, file af56fd43-07a1-4236-ad34-51fe9af5fc09
|
1
|
|
Synthesis and pharmacological evaluation of potent and enantioselective sigma-1 and sigma-2 ligands, file dfe4d226-f633-bb0a-e053-d805fe0a78d9
|
1
|
|
Evaluation of N-substitution in 6,7-benzomorphan compounds, file dfe4d226-fc05-bb0a-e053-d805fe0a78d9
|
1
|
|
Multitarget opioid ligands in pain relief: New players in an old game, file dfe4d226-fef7-bb0a-e053-d805fe0a78d9
|
1
|
|
(+)-cis-N-ethyleneamino-N-normetazocine derivatives. Novel and selective sigma
ligands with antagonist properties, file dfe4d226-ff20-bb0a-e053-d805fe0a78d9
|
1
|
|
Antinociceptive profile of LP1, a non-peptide multitarget opioid ligand., file dfe4d227-0617-bb0a-e053-d805fe0a78d9
|
1
|
|
The benzomorphan-based LP1 ligand is a suitable MOR/DOR agonist for chronic pain
treatment, file dfe4d227-13b8-bb0a-e053-d805fe0a78d9
|
1
|
|
New bifunctional antioxidant/σ1 agonist ligands: preliminary chemico-physical and biological evaluation, file dfe4d227-1717-bb0a-e053-d805fe0a78d9
|
1
|
|
Design and synthesis of new bifunctional sigma-1 selective ligands with antioxidant activity., file dfe4d227-237f-bb0a-e053-d805fe0a78d9
|
1
|
|
Novel potent and selective σ ligands: evaluation of their agonist and antagonist properties, file dfe4d227-2517-bb0a-e053-d805fe0a78d9
|
1
|
|
The Benzomorphan-Based Compound LP1 as Suitable Candidate for Pain Management, file dfe4d227-2855-bb0a-e053-d805fe0a78d9
|
1
|
|
(+)-and (−)-Phenazocine enantiomers: evaluation of their dual opioid agonist/σ1 antagonist properties and antinociceptive effects, file dfe4d227-3c4f-bb0a-e053-d805fe0a78d9
|
1
|
|
Opioid multiple ligands, file dfe4d227-546e-bb0a-e053-d805fe0a78d9
|
1
|
|
Non-peptide ligands for opioid receptors. Design of kappa-specific agonists, file dfe4d227-8ad9-bb0a-e053-d805fe0a78d9
|
1
|
|
Substituted 1-phenyl-2-cyclopropylmethylamines with high affinity and selectivity for sigma sites, file dfe4d227-b268-bb0a-e053-d805fe0a78d9
|
1
|
|
In vitro and in vivo pharmacological evaluation of LP1, a benzomorphan-based compound, file dfe4d228-7f44-bb0a-e053-d805fe0a78d9
|
1
|
|
Development of new benzomorphan LP1 analogues, file dfe4d228-83cb-bb0a-e053-d805fe0a78d9
|
1
|
|
Antioxidant properties and pharmacokinetic studies of new selective σ1 bifunctional ligands, file dfe4d228-8ea2-bb0a-e053-d805fe0a78d9
|
1
|
|
IDEBENONE LOADED LIPID NANOPARTICLES: EVALUATION OF IN VITRO ANTIOXIDANT ACTIVITY AND IN VIVO TOPICAL EFFECTS, file dfe4d228-ad89-bb0a-e053-d805fe0a78d9
|
1
|
|
Dual MOR/DOR agonist benzomorphan-based compounds for pain relief, file dfe4d228-b3c9-bb0a-e053-d805fe0a78d9
|
1
|
|
Benzomorphan scaffold for opioid analgesics and pharmacological tools development: A comprehensive review, file dfe4d228-e3c7-bb0a-e053-d805fe0a78d9
|
1
|
|
MOR/DOR targeting mediates neuropathic pain amelioration in chronic constriction injured rats., file dfe4d229-974a-bb0a-e053-d805fe0a78d9
|
1
|
|
Novel N-Substituted Benzomorphan-Based Compounds: From MOR-Agonist/DOR-Antagonist to Biased/Unbiased MOR Agonists, file dfe4d22a-f2a8-bb0a-e053-d805fe0a78d9
|
1
|
|
Benzomorphan skeleton, a versatile scaffold for different targets: A comprehensive review, file dfe4d22b-24ae-bb0a-e053-d805fe0a78d9
|
1
|
|
Dual Sigma-1 receptor antagonists and hydrogen sulfide-releasing compounds for pain treatment: Design, synthesis, and pharmacological evaluation, file dfe4d22e-c01c-bb0a-e053-d805fe0a78d9
|
1
|
| Totale |
1.210 |